Alcohol-associated liver disease (ALD) is a major cause of chronic liver disease worldwide,
and comprises a spectrum of several different disorders, including simple steatosis …

Steatotic liver diseases (SLDs) affect one-third of the population, but the pathogenesis
underlying these diseases is not well understood, limiting the available treatments. A …

Background Steatotic liver disease is a new overarching term that includes metabolic
dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol …

Background & Aims The long-term impact of alcohol-related public health policies (PHPs) on
disease burden is unclear. We aimed to assess the association between alcohol-related …

Non-alcoholic liver disease (NAFLD) is now metabolic dysfunction-associated steatotic liver
disease (MASLD), emphasizing the key metabolic factors of obesity, insulin resistance …

Nonalcoholic steatohepatitis (NASH) is an advanced stage of fatty liver disease
characterized by liver damage, inflammation, and fibrosis. Although neutrophil infiltration is …

Steatotic liver, characterized by the accumulation of fat in the liver, poses significant health
risks including metabolic dysfunction-associated steatotic liver disease (MASLD) and an …

MASLD prevalence is growing towards the leading cause of end-stage liver disease. Up to
today, the most effective treatment is weight loss. Weight loss interventions are moving from …

Lipid metabolism diseases have become a tremendous risk worldwide, along with the
development of productivity and particular attention to public health. It has been an urgent …

Background The prevalence of at‐risk metabolic dysfunction‐associated steatohepatitis (at‐
risk MASH) has not been systematically assessed. Aim To delineate the prevalence of at …